Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPDGF-BB for Infraorbital Hollowing
NCT07914816Phase 2Not yet recruiting
- Sponsor
- Lynch Regenerative Medicine
- Start
- Nov 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of becaplermin in infraorbital hollowing, sponsored by Lynch Regenerative Medicine. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
becaplermin
03
Conditions
infraorbital hollowing
Beyond the preview
Go deeper on NCT07914816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07914816.